NAD+: Discovery and Research History

Introduction

The research history of nicotinamide adenine dinucleotide (NAD+) is among the most extended in biochemistry, spanning more than 120 years across four distinct scientific eras: the initial discovery of a fermentation cofactor in the early twentieth century; the structural and functional characterization of the coenzyme through the 1930s to 1960s; the identification of NAD+ as a substrate for regulatory enzymes beginning in the 1960s and accelerating dramatically in 2000; and the contemporary clinical and translational research era focused on NAD+ precursor pharmacology. Each transition redefined the scientific understanding of what NAD+ is and what research questions it raises. A chemistry overview and regulatory summary is covered in the accompanying NAD+ research overview article.

Discovery Period: Harden, Young, and the Cofactor (1906–1929)

The discovery of what became known as NAD+ began in the study of alcoholic fermentation. In 1906, Arthur Harden and William John Young, working at the Lister Institute in London, reported in the Proceedings of the Royal Society of London that cell-free yeast extracts capable of fermenting glucose were rendered more active by addition of boiled (heat-treated) yeast extract [1]. Because heat denatured enzymatic proteins, the active component of the boiled extract was not a protein enzyme. A follow-up paper the same year demonstrated that the active material was dialysable — it passed through a semipermeable membrane that retained proteins — indicating a small-molecule cofactor [2]. Harden and Young designated this substance "cozymase," identifying it as a required cofactor for yeast-mediated glucose fermentation.

Harden and Hans von Euler-Chelpin shared the Nobel Prize in Chemistry in 1929 "for their investigations on the fermentation of sugar and fermentative enzymes." Von Euler-Chelpin had devoted more than a decade to characterizing the chemical composition of cozymase, establishing by the time of the Nobel award that it was a nucleotide-containing molecule with a dinucleotide structure — two nucleotide units joined by a phosphate bridge. His acceptance remarks described cozymase as "one of the most widespread and biologically most important activators within the plant and animal world."

Early Research: Structure, Redox Function, and the Niacin Connection (1930s–1950s)

The 1930s produced two parallel lines of progress that together defined NAD+ chemistry. Otto Heinrich Warburg turned his attention to pyridine coenzymes following his Nobel Prize-winning work on cellular respiration. In 1936, Warburg and colleagues demonstrated that the nicotinamide ring of the coenzyme was the chemically active moiety responsible for hydride transfer in biological oxidation reactions, identifying the C4 position of the pyridine ring as the hydrogen-accepting site. This established the mechanistic basis of NAD+ as a hydride carrier and placed it at the center of cellular respiratory metabolism. A structurally related but phosphorylated molecule — NADP+ — was identified in the same period, extending the pyridine nucleotide family.

Concurrently, research into pellagra — a nutritional deficiency disease then epidemic in the American South — connected NAD+ to dietary vitamin biology. Conrad Elvehjem and colleagues at the University of Wisconsin reported in 1937 that nicotinic acid (niacin) resolved "blacktongue," a disease in dogs analogous to human pellagra. This established nicotinic acid and its amide (nicotinamide) as dietary precursors to NAD+ and defined niacin (vitamin B₃) as a vitamin in the classical sense — a dietary compound whose deficiency produces a defined disease syndrome.

The biosynthetic pathways by which dietary niacin is converted to NAD+ were characterized in the late 1950s. Jack Preiss and Philip Handler published papers in the Journal of Biological Chemistry in 1958 describing the multi-step enzymatic conversion of nicotinic acid to NAD+ via intermediates including nicotinic acid mononucleotide and nicotinic acid adenine dinucleotide [3,4]. The Preiss-Handler pathway, as it became known, established the enzymatic logic of NAD+ synthesis from dietary niacin and remained the canonical biosynthetic framework for several decades.

Regulatory Milestones and the Sirtuin Era (1960s–2000s)

NAD+ was identified as the substrate for the first ADP-ribosylation reactions in the 1960s and 1970s. Chambon and colleagues and independently Sugimura and colleagues identified poly(ADP-ribose) polymerase (PARP) activity — enzymatic reactions that transfer ADP-ribose units from NAD+ to acceptor proteins — establishing for the first time that NAD+ was not only a redox cofactor but also a consumed substrate in signaling reactions. This finding implied that NAD+ availability could limit regulatory pathways under physiological conditions, a question that would take decades to investigate systematically.

The field was substantially reshaped in 2000 by Imai, Armstrong, Kaeberlein, and Guarente, who reported in Nature that Sir2 — a yeast silencing protein known to regulate replicative lifespan in that organism — was an NAD-dependent histone deacetylase [5]. This paper established that sirtuin enzymatic activity is obligately gated by NAD+ availability, and repositioned NAD+ from a metabolic cofactor to a regulatory signal linking cellular energy status to chromatin structure and gene regulation. The discovery that the sirtuin family is evolutionarily conserved from bacteria to mammals (SIRT1 through SIRT7 in humans) made this connection broadly relevant to mammalian cell biology. The 2000 paper stands as one of the most-cited works in the field and initiated a wave of follow-on research that continues today.

The same period saw characterization of CD38, a transmembrane enzyme studied previously in immunology contexts, as a major NADase — an enzyme that degrades NAD+ without producing poly-ADP-ribose. Recognition that multiple independent enzyme families (PARPs, sirtuins, CD38) compete for the same cellular NAD+ pool gave the coenzyme a role as a substrate at the intersection of DNA repair signaling, metabolic sensing, and immune regulation.

The Precursor Research Landscape (2004–Present)

A consequential development was the identification of nicotinamide riboside (NR) as a previously unrecognized dietary NAD+ precursor. Bieganowski and Brenner reported in Cell in 2004 that NR is taken up by cells via a distinct kinase-mediated pathway (the NRK pathway) that bypasses the previously characterized Preiss-Handler and de novo (tryptophan-derived) routes [6]. This discovery expanded the known NAD+ biosynthetic network and identified NR as a substrate capable of raising cellular NAD+ independently of nicotinic acid or nicotinamide — a distinction with pharmacological implications for subsequent clinical research.

The NRK pathway finding, combined with the growing evidence that SIRT1 activity is NAD+-gated and that rodent tissue NAD+ concentrations change with age, motivated a wave of preclinical and clinical research. Cantó and colleagues demonstrated in 2012 that dietary NR in mice activated SIRT1 and SIRT3 and altered mitochondrial biology in that model system [7]. The Gomes and Sinclair 2013 Cell study reporting a pseudohypoxic state in aged mouse tissues linked to declining NAD+ — and its partial reversal by NMN administration in that model — stimulated additional translational research [8].

Clinical pharmacokinetics of oral NR in humans were characterized by Trammell, Schmidt, and colleagues in 2016, documenting dose-dependent increases in blood NAD+ metabolites following oral NR in a first-in-human study [9]. Subsequent randomized controlled trials in humans have examined NR and NMN in healthy adults, older adults, and individuals with metabolic dysfunction, establishing the short-term safety profile of oral administration and confirming that these precursors measurably alter the blood NAD+ metabolome in humans. Functional metabolic outcomes across these trials are summarized in the accompanying published-research article.

Current Research Landscape

As of the mid-2020s, NAD+ research encompasses multiple active clinical and mechanistic fronts. The NR-SAFE trial (2023, Nature Communications) investigated NR in Parkinson's disease patients and reported that NR was well-tolerated and measurably elevated cerebral NAD+ as assessed by magnetic resonance spectroscopy — a technically significant methodological advance enabling non-invasive NAD+ measurement in living human brain tissue and opening a new window for neurological research applications.

Active clinical registrations span cardiovascular disease, Parkinson's disease, non-alcoholic fatty liver disease, COVID-19 sequelae, and neurodegeneration. Mechanistic investigations continue into which NAD+-consuming enzyme system most influences tissue NAD+ dynamics — PARP activation from cumulative DNA damage, CD38 upregulation in aged immune cells, or modulation of NAMPT-mediated salvage pathway activity. The ongoing resolution of these questions, combined with improving methods for tissue-level NAD+ measurement in humans, positions NAD+ research as a field with considerable unresolved scientific potential. NMN's regulatory classification and NR's NDI-acknowledged dietary supplement status both reflect the compound class's active regulatory and scientific engagement — a landscape that will continue to evolve as clinical evidence accumulates. Parallel mitochondrial research has examined MOTS-c, a mitochondria-derived peptide whose scientific characterization follows a comparably recent timeline. NAD+ from SpartaLabs is available as research-grade material with independently verified batch documentation.

References

1. Harden A, Young WJ. The alcoholic ferment of yeast-juice. Proc R Soc Lond B. 1906;77(519):405–420. DOI: 10.1098/rspb.1906.0029. https://royalsocietypublishing.org/doi/10.1098/rspb.1906.0029

2. Harden A, Young WJ. The alcoholic ferment of yeast-juice. Part II — The coferment of yeast-juice. Proc R Soc Lond B. 1906;78(526):369–375. DOI: 10.1098/rspb.1906.0070. https://royalsocietypublishing.org/doi/10.1098/rspb.1906.0070

3. Preiss J, Handler P. Biosynthesis of diphosphopyridine nucleotide. I. Identification of intermediates. J Biol Chem. 1958;233(2):488–492. PMID: 13563526. https://pubmed.ncbi.nlm.nih.gov/13563526/

4. Preiss J, Handler P. Biosynthesis of diphosphopyridine nucleotide. II. Enzymatic aspects. J Biol Chem. 1958;233(2):493–500. PMID: 13563527. https://pubmed.ncbi.nlm.nih.gov/13563527/

5. Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 2000;403(6771):795–800. DOI: 10.1038/35001622. https://pubmed.ncbi.nlm.nih.gov/10693811/

6. Bieganowski P, Brenner C. Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans. Cell. 2004;117(4):495–502. DOI: 10.1016/S0092-8674(04)00416-7. PMID: 15137942. https://pubmed.ncbi.nlm.nih.gov/15137942/

7. Cantó C, Houtkooper RH, Pirinen E, Youn DY, Oosterveer MH, Cen Y, et al. The NAD+ precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab. 2012;15(6):838–847. PMC3616313. https://pmc.ncbi.nlm.nih.gov/articles/PMC3616313/

8. Gomes AP, Price NL, Ling AJ, Moslehi JJ, Montgomery MK, Rajman L, et al. Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell. 2013;155(7):1624–1638. DOI: 10.1016/j.cell.2013.11.037. https://pubmed.ncbi.nlm.nih.gov/24360282/

9. Trammell SA, Schmidt MS, Weidemann BJ, Redpath P, Jaksch F, Dellinger RW, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016;7:12948. DOI: 10.1038/ncomms12948. https://www.nature.com/articles/ncomms12948